Morgan Stanley
ARQT icon

Morgan Stanley’s Arcutis Biotherapeutics ARQT Stock Holding History

Morgan Stanley’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$117M Buy
4,451,014
+232,083
+6% +$5.41M 0.01% 1437
2026
Q1 		$99.4M Sell
4,218,931
-121,308
-3% -$3.1M 0.01% 1446
2025
Q4 		$126M Buy
4,340,239
+63,845
+1% +$1.63M 0.01% 1250
2025
Q3 		$80.6M Sell
4,276,394
-38,136
-0.9% -$601K ﹤0.01% 1604
2025
Q2 		$60.5M Buy
4,314,530
+475,989
+12% +$6.67M ﹤0.01% 1744
2025
Q1 		$60M Sell
3,838,541
-405,370
-10% -$5.71M ﹤0.01% 1652
2024
Q4 		$59.1M Buy
4,243,911
+462,716
+12% +$5.07M ﹤0.01% 1685
2024
Q3 		$35.2M Sell
3,781,195
-191,499
-5% -$1.89M ﹤0.01% 2204
2024
Q2 		$36.9M Sell
3,972,694
-33,641
-0.8% -$304K ﹤0.01% 2037
2024
Q1 		$39.7M Sell
4,006,335
-2,076,737
-34% -$15.5M ﹤0.01% 1966
2023
Q4 		$19.6M Buy
6,083,072
+5,861,032
+2,640% +$15.9M ﹤0.01% 2704
2023
Q3 		$1.18M Sell
222,040
-263,938
-54% -$2.24M ﹤0.01% 4702
2023
Q2 		$4.63M Buy
485,978
+148,324
+44% +$1.65M ﹤0.01% 3834
2023
Q1 		$3.71M Buy
337,654
+139,590
+70% +$2.02M ﹤0.01% 4025
2022
Q4 		$2.93M Buy
198,064
+73,138
+59% +$1.28M ﹤0.01% 4189
2022
Q3 		$2.39M Buy
124,926
+16,757
+15% +$380K ﹤0.01% 4297
2022
Q2 		$2.3M Buy
108,169
+10,717
+11% +$220K ﹤0.01% 4420
2022
Q1 		$1.88M Buy
97,452
+44,433
+84% +$752K ﹤0.01% 4561
2021
Q4 		$1.1M Sell
53,019
-90,727
-63% -$1.81M ﹤0.01% 5001
2021
Q3 		$3.43M Sell
143,746
-82,927
-37% -$1.89M ﹤0.01% 4093
2021
Q2 		$6.18M Buy
226,673
+100,961
+80% +$2.84M ﹤0.01% 3558
2021
Q1 		$3.64M Sell
125,712
-26,298
-17% -$821K ﹤0.01% 3742
2020
Q4 		$4.28M Buy
152,010
+149,207
+5,323% +$3.65M ﹤0.01% 3423
2020
Q3 		$83K Sell
2,803
-770
-22% -$20.6K ﹤0.01% 5511
2020
Q2 		$108K Buy
3,573
+2,136
+149% +$61.7K ﹤0.01% 5371
2020
Q1 		$43K Buy
+1,437
New +$38.6K ﹤0.01% 5522

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley's ARQT Position: Q2 2026 in Review

Morgan Stanley increased its Arcutis Biotherapeutics (ARQT) stake by 5.5% in Q2 2026, buying an estimated $5.41M and bringing the position to 4,451,014 shares worth $117M. The position accounts for 0.01% of the portfolio, ranked #1437.

Morgan Stanley first reported a position in ARQT in Q1 2020 and has held it in 26 quarters since. The position peaked at $126M in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Morgan Stanley held 4,451,014 shares of Arcutis Biotherapeutics worth $117M as of Q2 2026.
  • Morgan Stanley bought 232,083 Arcutis Biotherapeutics shares in Q2 2026, an estimated $5.41M.
  • Arcutis Biotherapeutics made up 0.01% of Morgan Stanley's portfolio in Q2 2026, its #1437 holding.
  • Morgan Stanley first reported a position in Arcutis Biotherapeutics in Q1 2020 and has held it in 26 quarters since.
  • Morgan Stanley's Arcutis Biotherapeutics position peaked at $126M in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.